The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 9, 2017, Pages 1473-1479

  Yordanova, Anna ^a   Becker, Anja ^a   Eppard, Elisabeth ^a   Kürpig, Stefan ^a   Fisang, Christian ^a   Feldmann, Georg ^a   Essler, Markus ^a   Ahmadzadehfar, Hojjat ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

177Lu; Nephrotoxicity; Prostate cancer; PSMA; Radioligand therapy; Renal function

Indexed keywords

ABIRATERONE; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; CYSTATIN C; CYTOKINE RECEPTOR ANTAGONIST; ENZALUTAMIDE; FUROSEMIDE; LUTETIUM 177; MERTIATIDE TC 99M; PROSTATE SPECIFIC MEMBRANE ANTIGEN 617 LU 177; RADIOLIGAND; UNCLASSIFIED DRUG; DIPEPTIDE; HORMONE; LIGAND; LUTETIUM; LUTETIUM-177; PSMA-617; RADIOISOTOPE; SINGLE HETEROCYCLIC RINGS;

ADULT; AGED; ARTICLE; CANCER RADIOLIGAND THERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DOSIMETRY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PATIENT HISTORY OF CHEMOTHERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; URETER STENT; URINARY EXCRETION; URINARY TRACT OBSTRUCTION; KIDNEY; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; RADIATION RESPONSE; RISK FACTOR; TIME FACTOR; TREATMENT FAILURE;

AGED; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 1-RING; HORMONES; HUMANS; KIDNEY; LIGANDS; LUTETIUM; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RADIOISOTOPES; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE;

EID: 85015831312     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-017-3681-9     Document Type: Article

References (22)

1. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res: Off J Am Assoc Cancer Res. 1997;3:81–5.
2. Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014;28:555–63.
3. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50:472–83. doi:10.1111/j.1365-2559.2007.02635.x.
4. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39. doi:10.1002/jcb.10661.
5. Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z, et al. Targeted treatment of prostate cancer. J Cell Biochem. 2007;102:571–9. doi:10.1002/jcb.21491.
6. Jamous M, Haberkorn U, Mier W. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases. Molecules. 2013;18:3379–409. doi:10.3390/molecules18033379.
7. Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med: Off Publ Soc Nucl Med. 2015;56:914–20. doi:10.2967/jnumed.114.147413.
8. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med: Off Publ Soc Nucl Med. 2015;56:1697–705. doi:10.2967/jnumed.115.161299.
9. Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477–88. doi:10.18632/oncotarget.7245.
10. Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114. doi:10.1186/s13550-015-0114-2.
11. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. Journal of nuclear medicine: official publication. Soc Nucl Med. 2016. doi:10.2967/jnumed.116.183194.
12. Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. J Nucl Med: Off Publ Soc Nucl Med. 2016;57:1334–8. doi:10.2967/jnumed.116.173757.
13. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med: Off Publ Soc Nucl Med. 2016;57:1006–13. doi:10.2967/jnumed.115.168443.
14. Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med: Off Publ Soc Nucl Med. 2016;57:1170–6. doi:10.2967/jnumed.115.171397.
15. Schlenkhoff CD, Gaertner F, Essler M, Schmidt M, Ahmadzadehfar H. Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer. Clin Nucl Med. 2016. doi:10.1097/RLU.0000000000001195.
16. Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42–51. doi:10.1007/s00259-015-3174-7.
17. Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976–83. doi:10.1007/s00259-015-3125-3.
18. Ferdinandus J, Eppard E, Gaertner FC, Kurpig S, Fimmers R, Yordanova A, et al. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617. J Nucl Med: Off Publ Soc Nucl Med. 2017;58:312–9. doi:10.2967/jnumed.116.178228.
19. National Cancer Institute Guidelines For Investigators: Adverse event reporting requirements for DCTC DCTD (CTEP and CIP) and DCP INDs and IDEs. 2013.
20. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6. doi:10.1053/ajkd.2002.34487.
21. Prozialeck WC, VanDreel A, Ackerman CD, Stock I, Papaeliou A, Yasmine C, et al. Evaluation of cystatin C as an early biomarker of cadmium nephrotoxicity in the rat. Biometals. 2016;29:131–46. doi:10.1007/s10534-015-9903-3.
22. Dubovsky EV, Russell CD. Quantitation of renal function with glomerular and tubular agents. Semin Nucl Med. 1982;12:308–29.